Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The Committee for Medicinal Products for Human Use or CHMP has adopted a positive opinion to recommend the variation to the terms of the marketing authorization for Eli Lilly's Forsteo.
Subscribe to our email newsletter
Forsteo is intended for the treatment of osteoporosis associated with sustained systemic glucocorticoid therapy in women and men at increased risk for fracture.